ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CMND / news
ERNA (33) EOCN (34) MBIO (41) SXTP (38) ⌘ Pro Terminal →

Why CMND Stock slipped -1.27% Today — RQD Quant Desk Flash

$6.14 -1.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.11

Clearmind Medicine Inc. (CMND) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CMND Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CMND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Clearmind Medicine Inc. (NASDAQ: CMND) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $6.14 (-1.27% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, CMND ranks #319 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CMND compare to ERNA and EOCN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMND carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and EOCN (Eocene Ltd.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M). Among the 5-stock peer group, CMND leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CMND?
▼

For Clearmind Medicine Inc. (CMND), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #319 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.11 (-0.42%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
$2822 Bull$6 Base$5 Bear
📬 FREE CMND RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CMND)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY CMND SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($88.4K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$6.23-1.8% Next Q
Q2 (-2Q)
52
Grade C-$6.12-2.5% Next Q
Q3 (-1Q)
50
Grade C-$5.97+2.8% Next Q
Current
47
Grade D$6.14-5.9% Hist 90D α
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CMND Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CMND currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.78) and Max Pain ($6.45) forces dealer call-delta covering toward $2,822.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CMND• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CMND Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why CMND Stock slipped -1.27% Today — RQD Quant Desk Flash

Clearmind Medicine Inc. (CMND) slipped -1.27% to $6.14, trading at 2% of its 52-week range ($5.25 – $2688). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($5.25 – $2688) with RSI-14 at 44.9 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $6.14 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $88354 annual free cash flow.
Live CMND Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CMND)

  • ✓Walkthrough of CMND's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CMND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.63%▲ RESISTANCE BREAKOUT
2026-11-03O $5.85H $6.22L $5.85C $6.14VOL 10.5K
RES: $6.04SUP: $2.61SMA50: $7.78SMA200: $45.92
$1,509.3$1,101.7$694.0$286.4$-121.26RES $6.04SUP $2.61$6.142026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CMND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CMND Butterfly Map → + Track CMND →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CMND today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CMND. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CMND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CMND)

Health Care Rank #319 of 1015 ⚔️ ERNA vs CMND Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CMND vs. ERNA, EOCN, MBIO, SXTP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Clearmind Medicine Inc. (CMND) ranks #319 by composite RQD confidence (47/100, grade D) and #975 by equity capitalization ($3.2M). Within this direct 5-issuer industry benchmark cohort, CMND leads on earnings valuation at N/A trailing P/E, while ERNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CMND currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CMND ACTIVE
Clearmind Medicine Inc.
D 47/100 — — — -1.27% $3.2M Benchmark Subject
ERNA
Ernexa Therapeutics Inc.
E 33/100 — — -35.0% -1.01% $3.2M /erna-vs-cmnd →
EOCN
Eocene Ltd.
E 34/100 — — -35.0% -7.54% $3.2M /eocn-vs-cmnd →
MBIO
Mustang Bio Inc.
D- 41/100 — — -35.0% +3.72% $3.0M /mbio-vs-cmnd →
SXTP
60 Degrees Pharmaceuticals Inc.
D- 38/100 — 22.3% -35.0% -3.65% $3.3M /sxtp-vs-cmnd →

2. CMND Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Clearmind Medicine Inc. (CMND) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $3.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. CMND Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CMND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Clearmind Medicine Inc. (NASDAQ: CMND) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $6.14 (-1.27% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, CMND ranks #319 in composite RQD confidence.

How does CMND compare to ERNA and EOCN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMND carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and EOCN (Eocene Ltd.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M). Among the 5-stock peer group, CMND leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CMND?

For Clearmind Medicine Inc. (CMND), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #319 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CMND trading relative to its 50-day, 200-day, and 52-week technical levels?

CMND last traded at $6.14 (-1.27% on volume of 2,244 shares), positioning the stock -21.08% below its 50-day simple moving average ($7.78) and -86.63% below its 200-day simple moving average ($45.92). Across its 52-week range of $5.25 to $2,688.00, CMND sits at the 0.0% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.37 to $6.91).

Direct Sub-Reports: CMND RQD Cockpit CMND 12M Forecast CMND Earnings & Move CMND Dividends & DRIP CMND Insiders & 13F CMND Whale Options CMND Profit Sankey CMND News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

CMND — Clearmind Medicine Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Clearmind Medicine Inc. (CMND) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $6.14 (-1.27% 1D, market capitalization $3.2M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Clearmind Medicine Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..0B. Per the news wire, the company is associated with a clinical program for CMND-100 in alcohol use disorder, and a subsidiary has launched a robotaxi-related charging system.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $5.25 – $2,688.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. Investors should note that the only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations.

  • Key Question #1: Can CMND sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $2,688.00 52-week high?
  • Key Question #3: How sensitive is CMND's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CMND Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Clearmind Medicine Inc. (CMND) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CMND Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CMND Bull vs. Bear Conversation Board — What's Your Call at $6.14?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CMND 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CMND:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $8.15 (+31.0%)
📌 Pinned Debate

The forensic balance sheet pillar (13 / 20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the rating's relatively stronger area, a

Don't sleep on CMND's setup in Health Care. The forensic balance sheet pillar (13 / 20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the rating's relatively stronger area, and news flow reports completed patient recruitment in the CMND-100 trial.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (47/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — CMND's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $4.85 (-22.0%)
Spot @ $6.22

Institutional flow scores 3 / 20 as a distribution warning, with ROIC and FCF yield both at 0%, and no earnings or analyst data availab

Sitting on the sidelines or leaning short CMND above $6.22. Institutional flow scores 3 / 20 as a distribution warning, with ROIC and FCF yield both at 0%, and no earnings or analyst data available to anchor the $5.85 price.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $2688.00.

LIVE TAPE